Related references
Note: Only part of the references are listed.Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
Linong Ji et al.
DIABETES OBESITY & METABOLISM (2021)
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes
Michiko Asano et al.
DIABETES OBESITY & METABOLISM (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Leigh Perreault et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects
Lai-San Tham et al.
DIABETES (2021)
Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
Yanyun Chen et al.
DIABETES (2021)
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
Linong Ji et al.
ECLINICALMEDICINE (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study
Maria Alba et al.
CLINICAL OBESITY (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study
Nicholas A. Di Prospero et al.
CLINICAL OBESITY (2021)
Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss
Mette S. Nielsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study
Kleopatra Alexiadou et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes
Jennifer Trujillo
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2020)
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials
Nikolaos Perakakis et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Patrick J. Knerr et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D. Ambery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
N. H. Cho et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Hemodynamic Effects of Glucagon: A Literature Review
Kasper Meidahl Petersen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
R. Scott et al.
PEPTIDES (2018)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Martin Lorenz et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists
Brian Finan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Action and therapeutic potential of oxyntomodulin
Alessandro Pocai
MOLECULAR METABOLISM (2014)
Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
Tricia M. Tan et al.
DIABETES (2013)
Oxyntomodulin increases intrinsic heart rate through the glucagon receptor
Auyon Mukharji et al.
PHYSIOLOGICAL REPORTS (2013)
Share Paper
